Patents Assigned to Integrated DNA Technologies, Inc.
-
Publication number: 20090118482Abstract: The invention provides a novel method of labeling oligonucleotides, with reporter moieties, including but not limited to, quenchers, fluorophores, biotin, digoxigenin, peptides and proteins. In addition, this invention provides a method of detecting hybridization of oligonucleotides. This invention also provides novel azo quenchers having the general formula shown below. The invention further provides compositions comprising labeled oligonucleotides and solid supports. The invention also provides kits comprising at least one composition of the present invention.Type: ApplicationFiled: January 12, 2009Publication date: May 7, 2009Applicant: INTEGRATED DNA TECHNOLOGIES, INC.Inventors: Andrei Laikhter, Joseph A. Walder, Mark Behlke, Mikhail Podyminogin, Yawfui Yong
-
Publication number: 20090068643Abstract: The present invention provides novel nucleotide compositions that enable the detection of DNA synthesis products and methods for use thereof. In one embodiment, the method can be used in PCR and allows the progress of the reaction to be monitored as it occurs. In one embodiment, the invention employs at least one fluorescence-quenched oligonucleotide that can prime DNA extension reactions. In a second embodiment, the invention employs at least one fluorescence-quenched oligonucleotide that can function as a template for DNA extension reactions. In both embodiments, the oligonucleotide also functions as a probe for detecting the progress of successive extension reaction cycles. Signal detection is dependent upon DNA synthesis and can occur with or without probe cleavage.Type: ApplicationFiled: November 24, 2006Publication date: March 12, 2009Applicant: INTEGRATED DNA TECHNOLOGIES, INC.Inventors: Mark A. Behlke, Joseph A. Walder
-
Publication number: 20090053821Abstract: Disclosed is a group of azo quencher compositions useful as fluorescence quenchers having the general structure of formula 1, methods of making or using the compositions, and kits comprising the composition.Type: ApplicationFiled: October 16, 2008Publication date: February 26, 2009Applicant: INTEGRATED DNA TECHNOLOGIES, INC.Inventors: Andrei Laikhter, Mark Aaron Behlke, Joseph Walder, Kevin William Roberts, Yawfui Yong
-
Publication number: 20090043085Abstract: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.Type: ApplicationFiled: June 20, 2008Publication date: February 12, 2009Applicants: CITY OF HOPE, INTEGRATED DNA TECHNOLOGIES, INC.Inventors: John J. ROSSI, Mark A. BEHLKE, Dongho KIM
-
Publication number: 20090043083Abstract: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.Type: ApplicationFiled: June 12, 2008Publication date: February 12, 2009Applicants: CITY OF HOPE, INTEGRATED DNA TECHNOLOGIES, INC.Inventors: John J. ROSSI, Mark A. BEHLKE, Dongho KIM
-
Publication number: 20090036661Abstract: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.Type: ApplicationFiled: June 20, 2008Publication date: February 5, 2009Applicants: CITY OF HOPE, INTEGRATED DNA TECHNOLOGIES, INC.Inventors: John J. ROSSI, Mark A. BEHLKE, Dongho KIM
-
Publication number: 20090035854Abstract: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.Type: ApplicationFiled: June 20, 2008Publication date: February 5, 2009Applicants: CITY OF HOPE, INTEGRATED DNA TECHNOLOGIES, INC.Inventors: John J. ROSSI, Mark A. BEHLKE, Dongho KIM
-
Publication number: 20090029466Abstract: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.Type: ApplicationFiled: June 20, 2008Publication date: January 29, 2009Applicants: CITY OF HOPE, INTEGRATED DNA TECHNOLOGIES, INC.Inventors: John J. ROSSI, Mark A. BEHLKE, Dongho KIM
-
Publication number: 20090029936Abstract: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.Type: ApplicationFiled: June 20, 2008Publication date: January 29, 2009Applicants: CITY OF HOPE, INTEGRATED DNA TECHNOLOGIES, INC.Inventors: John J. ROSSI, Mark A. BEHLKE, Dongho KIM
-
Publication number: 20090018321Abstract: The invention provides compositions and methods for selectively reducing the expression of a gene product from a desired target gene, as well as treating diseases caused by expression of the gene. The method involves introducing into the environment of a cell an amount of a double-stranded RNA (dsRNA) such that a sufficient portion of the dsRNA can enter the cytoplasm of the cell to cause a reduction in the expression of the target gene. The dsRNA has a first oligonucleotide sequence that is between 26 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of from about 19 to about 23 nucleotides is complementary to a nucleotide sequence of the RNA produced from the target gene.Type: ApplicationFiled: June 12, 2008Publication date: January 15, 2009Applicants: INTEGRATED DNA TECHNOLOGIES, INC., CITY OF HOPEInventors: John J. ROSSI, Mark A. BEHLKE, Dongho KIM
-
Patent number: 7476735Abstract: The invention provides a novel method of labeling oligonucleotides, with reporter moieties, including but not limited to, quenchers, fluorophores, biotin, digoxigenin, peptides and proteins. In addition, this invention provides a method of detecting hybridization of oligonucleotides. This invention also provides novel azo quenchers having the general formula shown below. The invention further provides compositions comprising labeled oligonucleotides and solid supports. The invention also provides kits comprising at least one composition of the present invention.Type: GrantFiled: May 22, 2006Date of Patent: January 13, 2009Assignee: Integrated DNA Technologies, Inc.Inventors: Andrei Laikhter, Joseph A. Walder, Mark Behlke, Mikhail Podyminogin, Yawful Yong
-
Publication number: 20090011422Abstract: This invention pertains to methods for cloning microRNA (miRNA) and other small ribonucleic acid (RNA) species from relevant cell sources.Type: ApplicationFiled: June 30, 2008Publication date: January 8, 2009Applicant: INTEGRATED DNA TECHNOLOGIES, INC.Inventors: Eric J. Devor, Lingyan Huang, Mark A. Behlke, Andrei Laikhter
-
Patent number: 7439341Abstract: Disclosed is a group of azo quencher compositions useful as fluorescence quenchers having the general structure of formula 1, methods of making or using the compositions, and kits comprising the composition.Type: GrantFiled: November 12, 2004Date of Patent: October 21, 2008Assignee: Integrated DNA Technologies, Inc.Inventors: Andrei Laikhter, Mark Aaron Behlke, Joseph Walder, Kevin William Roberts, Yawfui Yong
-
Publication number: 20080139797Abstract: This invention pertains to methods for oligonucleotide synthesis, specifically the synthesis of oligonucleotides that contain a high content of guanine monomers. In more detail, the invention relates to a method for coupling a nucleoside phosphoramidite during the synthesis of an oligonucleotide to a universal support, to a first nucleoside, or to an extending oligonucleotide. The invention further relates to oligonucleotides obtainable by the methods of the invention.Type: ApplicationFiled: December 12, 2007Publication date: June 12, 2008Applicant: INTEGRATED DNA TECHNOLOGIES, INC.Inventor: Brian Stephen Sproat
-
Publication number: 20080119563Abstract: The invention provides tetraalkyl ammonium fluoride derivatives or a pyridine hydrogen fluoride complex to remove silyl protecting groups in oligoribonucleotides synthesis.Type: ApplicationFiled: November 15, 2007Publication date: May 22, 2008Applicant: INTEGRATED DNA TECHNOLOGIES, INC.Inventors: Andrei Laikhter, William Martin, Erin Edgar
-
Publication number: 20080102531Abstract: The invention provides a method for evaluating the accuracy of an oligonucleotide sample, specifically a sample containing a variety of oligonucleotides of potentially varying size and sequence. The method provides a fingerprint that can be used to evaluate the accuracy of a multi-oligonucleotide sample whether or not the sample contains differing oligonucleotides that have the same or about the same molecular weight.Type: ApplicationFiled: October 23, 2007Publication date: May 1, 2008Applicant: Integrated DNA Technologies, Inc.Inventor: Brian Elliott
-
Publication number: 20070265220Abstract: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.Type: ApplicationFiled: May 1, 2007Publication date: November 15, 2007Applicants: City of Hope, Integrated DNA Technologies, Inc.Inventors: John Rossi, Mark Behlke, Dongho Kim
-
Patent number: 7276337Abstract: The present invention relates to methods for detecting the presence of ribonuclease enzymes, more specifically to methods that provide for a visual detection assay. The methods entail contacting a test sample suspected of containing ribonuclease activity with a substrate containing a ribonuclease-sensitive internucleotide linkage flanked directly or indirectly by a fluorescence reporter group and a dark quencher, such that if a ribonuclease activity is present in the sample, the ribonuclease-sensitive internucleotide linkage is cleaved and the fluorescence reporter group emits a visually detectable signal. The present invention further provides novel nucleic acid compositions used as substrates for such assays and encompasses kits for performing the methods of the invention.Type: GrantFiled: October 27, 2003Date of Patent: October 2, 2007Assignee: Integrated DNA Technologies, Inc.Inventors: Joseph Alan Walder, Mark Aaron Behlke, Eric Jeffrey Devor, Lingyan Huang
-
Publication number: 20070218490Abstract: The invention provides nucleic acid monomers with a 2?-modification that are useful for the incorporation of dyes or blocking groups. The monomers can be incorporated on the 3?-end of a dual labeled probe to inhibit PCR polymerase extension during PCR. The polymerase is inhibited from extending the probe at the 3?-hydroxyl group when the monomer is present; there is no need to add a chemical moiety to the 3?-hydroxyl or remove the 3?-hydroxyl. The monomers can also be incorporated internally or at the 5?-end of the oligonucleotide. A detectable label, such as a fluorescent or quenching dye, can be incorporated on the 2?-position of such monomers.Type: ApplicationFiled: March 15, 2007Publication date: September 20, 2007Applicant: INTEGRATED DNA TECHNOLOGIES, INC.Inventors: Andrei Laikhter, Joseph Walder, Mark Behlke
-
Publication number: 20060263816Abstract: The invention provides a novel method of labeling oligonucleotides, with reporter moieties, including but not limited to, quenchers, fluorophores, biotin, digoxigenin, peptides and proteins. In addition, this invention provides a method of detecting hybridization of oligonucleotides. This invention also provides novel azo quenchers having the general formula shown below. The invention further provides compositions comprising labeled oligonucleotides and solid supports. The invention also provides kits comprising at least one composition of the present invention.Type: ApplicationFiled: May 22, 2006Publication date: November 23, 2006Applicant: Integrated DNA Technologies, Inc.Inventors: Andrei Laikhter, Joseph Walder, Mark Behlke, Mikhail Podyminogin